Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

HER2DX® Genomic Test Shows Promise in HER2-Positive Advanced Gastric Cancer

NextEdge Admin

28 Jun 2024

2 min 42 sec

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up specializing in precision oncology, unveiled promising findings at the ESMO Gastrointestinal Cancers Congress 2024 in Munich. Their study, titled “HER2DX ERBB2 mRNA assay Following Trastuzumab-Based Chemotherapy in HER2-Positive Advanced Gastric Cancer,” showcased the efficacy of HER2DX® genomic testing in refining patient selection for trastuzumab-based chemotherapy in HER2-positive advanced gastric cancer.

The study underscored the variability in treatment response among patients with HER2+ advanced gastric cancer, emphasizing the critical need for precise biomarkers. HER2DX® emerged as a pivotal tool by quantifying ERBB2 mRNA expression levels and categorizing tumor samples into low, medium, and high groups. This classification not only enhances patient selection but also informs tailored treatment strategies.

CEO Patricia Villagrasa highlighted the milestone achievement of applying HER2DX® beyond breast cancer for the first time, illustrating its versatility across different oncological contexts. The test's capability to improve patient outcomes marks a significant advancement in personalized medicine.

Dr. Tamara Saurí, principal investigator at Hospital Clinic of Barcelona, stressed the test's potential to elucidate why HER2-positive gastric cancers often exhibit poorer responses compared to breast cancers. The study, involving 60 patients across Spanish hospitals, demonstrated HER2DX®'s effectiveness with a notable hazard ratio indicating reduced progression risk and improved survival outcomes associated with higher ERBB2 mRNA levels.

Additionally, comparative analysis with breast cancer highlighted nuances in ERBB2 expression, underscoring the test's role in quantifying this target across different cancer types.

REVEAL GENOMICS® continues to innovate within oncology, aiming to redefine biomarker utilization through advanced diagnostic tools. Their focus remains on leveraging cutting-edge technologies and data analytics to drive personalized treatment strategies and improve patient care in cancer therapeutics.